The role of healthcare cost accounting in pricing and reimbursement in low- and middle-income countries

Lorna Guinness (ORCID -0000-0002-1013-4200), PhD, Center for Global Development, London, United Kingdom

Srobana Ghosh, MSc, Center for Global Development, London, United Kingdom

Abha Mehndiratta, MBBS, DCH, DNB, MPH, Center for Global Development, London, United Kingdom

Hiral Anil Shah (ORCID - 0000-0003-0204-451X), MRC Center for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, London, UK.

Corresponding author

✉ Lorna Guinness
Great Peter House,
Abbey Gardens,
Great College St,
London
SW1P 3SE
Email: lornaguinness@gmail.com
Phone: +447926674052

Word count: 3959
Number of pages: 30
Number of figures: 5
Number of tables: 2
Supplementary materials: Pages 3, Tables 2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Abstract

Background

Progress towards universal health coverage requires evidence based policy and good quality cost data systems. Establishing these systems, can be complex, resource intensive and take time. Synthesising information on the experiences of low-and-middle income countries (LMICs) in trying to institutionalize cost data systems provides lessons for other settings.

Methods

We performed a scoping literature review, screening for publicly available peer-reviewed English-language publications alongside a grey literature search, focussing on national level health system costing in LMICs, and used a narrative synthesis approach to document experience of costing and how costing evidence is used to inform tariffs.

Results

A total of 484 papers were initially identified of which 30 papers were considered eligible. Fourteen papers reported on primary cost data collection for price-setting purposes; 18 papers provided an explanation of how cost evidence informs tariff-setting. Documented experience is largely focussed in the Asia region (n = 22) with countries at different stages of developing cost systems to inform tariff setting. Country experiences on healthcare cost accounting tend to showcase country costing experiences, methods and implementation. There is little documentation of how cost data has been incorporated into decision making and price setting. Where cost data, cost systems and costing has been used, improved transparency in decision making alongside increased service provision efficiency has followed.

Conclusions

While there are accepted and widely used methods for generating cost information, countries need to build sustainable cost systems appropriate to their settings and budgets and adopt transparent processes and methodologies for translating costs into prices.
INTRODUCTION

Low-and-middle income countries (LMICs) have been making significant progress towards universal health coverage through innovative healthcare financing. One focus of healthcare financing reforms has been reimbursement schemes that target the explicit goals of efficiency and cost containment while improving quality and reaching the poor and vulnerable. Historically, block grants have been used to reimburse healthcare providers in publicly financed systems in LMICs. However, as national-level public purchasers have evolved and a broader range of healthcare providers (e.g. private or faith-based healthcare providers) are accepted as part of the developing health system, newer prospective payment mechanisms and systems of provider reimbursement are being used by government purchasers of healthcare [1].

Common prospective payment mechanisms such as case-based payments for the reimbursement of secondary and/or tertiary care and capitation payments for primary care providers are now being championed across developing regions and countries. Case-based payments are equivalent to a system where providers are reimbursed based on cases treated rather than per service or per bed days [2]. On the other hand, capitation based payments are equivalent to a payment system where lump-sum payments are made to care providers based on the number of patients in a target population [2,3].

Setting reimbursement rates requires a reliable cost evidence base to enable price negotiations that are transparent, facilitate cost control and help drive providers to more efficient services. In principle, information is needed on the average cost per case across all admissions and/or visits (a base rate) and the relative value of different conditions as classified in the respective country (e.g., Diagnosis Related Groups, specialty-based classification, intervention specific health benefit package etc) [4–6]. In a case-based payment scheme, the service groups are often DRGs or a similar grouping system which provides a means of relating the type of patients a hospital treats to the costs incurred by the hospital. For capitation-based systems the grouping is related to the average expected cost of treating a patient under the care of the provider. In both types of system, the technical process of price-setting requires a robust cost system
to be in place, using principles that can be guided or even mandated by a purchaser, in order to generate reliable health service cost estimates.

Raulinajtys-Grzybek (2014) defines the cost system as “a cost accounting system that ensure the cost homogeneity of individual groups (of services)” [7]. There are however variation in costing systems across health systems as a result of choices about the process of collecting and verifying the data, the stage of development of the reimbursement system, the regulation around cost accounting and the costing methodology used [7]. For example, they can vary from one off costing studies to regular national costing surveillance [7,8]. Some cost surveys involve all participating providers e.g., in the UK and Australia all providers are mandated to submit cost accounting information; in others, only a sample of representative providers is used e.g. France, Germany and Thailand [9].

In terms of costing methodology, according to Gapenski and Reiter (2016) “the holy grail of cost estimation is costing at the service or individual patient level” [10]. More advanced systems e.g., those in the UK and Australia use bottom-up style costing methods to derive patient level DRG costs [11]; but there are simplified methods available that calculate the average cost of procedure through step down allocation methods [12]. Whichever approach is taken, it is important that the costing is nationally acceptable and can capture structural differences in cost that might be present (types of provider, demography, geography etc) as well as variability between the cost of the conditions treated. In addition, the national costing system should be standardised across providers, creating transparency and comparability [8].

In LMICs, while the process of payment reform has been well documented, there is less information available about the role of cost information in the technical process of setting reimbursement rates. Increasing number of countries are moving towards case-based payment schemes for secondary care within their UHC strategies. Documenting the cost systems used to generate evidence for rate setting can provide lessons for the further development of existing systems or the establishment of new ones. The aim of this paper is therefore to synthesise the evidence on the role of cost accounting in setting
reimbursement rates for case-based payment schemes in LMICs. We perform a scoping literature review and narrative synthesis to document the current practice in LMICs based on publicly available information and recommend steps for the technical process of price-setting in LMICS in the context of UHC goals.

METHODS

Search Strategy and Selection Process
A scoping review approach was used to synthesise the evidence on cost accounting in LMICs. We aimed to map the body of literature, clarify key concepts and identify any gaps in the research [13]. We further refined our research question using a standard PICO framework:

- Problem: technical process for price setting for hospital case-based payments in LMICs
- Intervention: cost systems
- Comparator: non-cost-based methods
- Outcome: improved evidence base for decision-making

We used several approaches in identifying the literature. First, we conducted a search of the literature for peer-reviewed English-language publications indexed in Pubmed, Medline, Econlit and in the Web of Science on the subject of national level health system costing in LMICs and the associated design of their costing systems. Our search was conducted using the following terms: ("case*mix" or "cost systems" or "cost*accounting" or "ref*costs" or "resource weights" or "cost*weights" or "national reimbursement" or "DRG" or "hospital payment systems" or "fee*for*service") AND ("LMIC" or "low resource settings" or "developing countries"). We conducted a search that included the country name of all LMICs, as defined by the World Bank. To complement this, we consulted existing libraries of both grey and peer-reviewed literature held by the research team. We then conducted an analysis of text words contained in the title and abstract to help identify further keywords and index terms. A further search was then conducted using the identified keywords and index terms. Finally, the reference list of all identified reports and articles
were reviewed for any reports or papers that might have been missed. The search strategy is provided in the Supplement.

**Eligibility Criteria & Screening**

Papers in the English language and published since 2000 were included. Results were then hand screened to ensure that the topic was limited to the eligible countries (LMICs as defined by the World Bank) and that the study identified and/or described the development of the national tariffs for hospital reimbursements and/or the methods used to estimate or inform the tariffs for hospital services reimbursement. The titles and abstracts were screened independently by two reviewers as per the inclusion and exclusion criteria defined by the study. The second screen involved reviewing full texts.

**Data Extraction & Synthesis**

The papers were then classified according to whether they explained the technical process of price-setting for reimbursements (i.e., if and how cost data was used) and whether they reported on the process of primary cost data collection for price-setting. For those papers or case studies reporting on the process of primary cost data collection for price setting, we extracted information on the method of cost data collection, the output and any commentary on how the cost data was used for price setting for hospital case-based payments including identifying the commissioning agency. From the papers that described how cost data is used in price setting, we extracted information on any description of the technical aspects of the tariff setting system in place, at the time of the study, and the key strengths and challenges of the approach used. For those papers describing more than one country experience, only evidence on LMIC experience was extracted. We use a narrative review approach to summarise the evidence by country. Data extraction was performed by one reviewer and then checked independently.
RESULTS

Overview of the literature

A total of 484 papers were initially identified of which 424 papers were excluded in the initial screening. The second screen involved reviewing full texts, leading to the inclusion of 30 papers in the review as described in the PRISMA diagram in Figure 1.

Of the 30 papers extracted, 7 papers stated a global focus (including LMICs) [1,4,14–18] and one paper reported to be focussed on the Asia region [19] (see Figure 2). Of the single country focussed papers, 6 related to India [20–25]. We found 3 studies each related to Thailand [6,26,27] and Vietnam [28–30]. There were 2 studies focussed on each of Indonesia [31,32], Iran [33,34], Malaysia [35,36] and Cambodia [37,38] and one study each for Kenya [39] and China [40]. Further, within the global papers, we identified case studies on: Kazakhstan, Kyrgyzstan, India, Malaysia, Thailand, and China.

Papers reporting on primary collection of cost data to inform tariff-setting

Twenty-three case studies from 14 fourteen studies reported on primary cost data collection for price setting purposes in a single country setting, either describing methods or both methods and results (see Table 1). Twelve case studies also had the explicit aim of generating cost information for broader policy processes. In terms of pricing, two case studies reported on a costing exercise that was designed to inform capitation payment rates [16,31], six studies aimed at generating cost weights for DRGs [4,16,36]¹ or unspecified case groups [16,27,29]² and three papers reported on estimation of the cost of health benefit packages [16,25]³. A final case study reviewed the available cost evidence for informing price setting in the National Health Insurance Fund, Kenya [39].

¹ Joint Learning Network case studies: Central Asian Republics
² Joint Learning Network case studies: Indonesia Ministry of Health
³ Joint Learning Network case studies: PhilHealth and India Aaorgyasri
Table 1. Costing evidence for tariff setting in hospital payment schemes in LMICs

<table>
<thead>
<tr>
<th>Year</th>
<th>Author</th>
<th>Country/Region</th>
<th>Type of study</th>
<th>Method of cost data collection</th>
<th>Generated output (what form does the cost data take e.g. Unit costs, DRG cost weights, base rates)</th>
<th>What is/was the cost data used for or what is the intended use</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>Prinja S et al</td>
<td>India</td>
<td>Primary (cost data)</td>
<td>Step down allocation; mix of top down and bottom-up costing</td>
<td>Reference costs to inform price setting and HTA</td>
<td>Comparison of health benefit package reimbursement rates with costs; use in HTA</td>
</tr>
<tr>
<td>2021</td>
<td>Dianingati RS et al</td>
<td>Asia</td>
<td>Literature review</td>
<td>Methods used in hospital cost analysis in Asia include direct allocation, step-down allocation, simultaneous equation allocations, micro costing and simplified activity-based costing.</td>
<td>Different final outputs include average costs, patient level (micro) costs, RVUs and RCCs.</td>
<td>Not reported for the studies in the review</td>
</tr>
<tr>
<td>2019</td>
<td>Jacobs B et al</td>
<td>Cambodia</td>
<td>Primary (cost data)</td>
<td>Step down allocation; bottom-up costing</td>
<td>Costs of health services</td>
<td>Initial phase of establishing a routine costing system for health services</td>
</tr>
<tr>
<td>2019</td>
<td>Dianingati JK et al</td>
<td>Indonesia</td>
<td>Primary (cost data)</td>
<td>Step down allocation: micro costing</td>
<td>Unit cost of the laboratory services of a district hospital in Indonesia</td>
<td>To compare actual costs of laboratory services with government established reference prices</td>
</tr>
<tr>
<td>2018a</td>
<td>Vo TQ et al</td>
<td>Vietnam</td>
<td>Primary (cost data)</td>
<td>Step down allocation; Micro-costing</td>
<td>Relative value units (RVUs) for hospital services</td>
<td>Develop a set of RVUs for hospital services in Vietnam</td>
</tr>
<tr>
<td>2018b</td>
<td>Vo TQ et al</td>
<td>Vietnam</td>
<td>Primary (cost data)</td>
<td>1. Step down allocation; Micro-costing. 2. Hospital charges</td>
<td>Relative value units (RVUs) for hospital services</td>
<td>Comparison of different methods and identification of best method for the estimation of RVUs</td>
</tr>
<tr>
<td>2018</td>
<td>Stenberg K et al</td>
<td>Global</td>
<td>Primary</td>
<td>WHO-CHOICE service delivery unit costs based on regression analysis of country data sets</td>
<td>Cost per bed-day and cost per outpatient visit</td>
<td>Address cost information gap by producing standardised cost estimates that are comparable across countries</td>
</tr>
<tr>
<td>2016</td>
<td>Ocharot L et al</td>
<td>Thailand</td>
<td>Primary (cost data)</td>
<td>Hospital charges</td>
<td>Uncompensated adverse event costs for hospitalised patients</td>
<td>To demonstrate the cost implications of patient safety</td>
</tr>
<tr>
<td>2015</td>
<td>Jadoo SAA et al</td>
<td>Malaysia</td>
<td>Primary (cost data)</td>
<td>Step down allocation; bottom-up costing</td>
<td>DRG cost weights for pharmacy services</td>
<td>To identify the actual cost of pharmacy services by DRG case-mix group and inform reimbursement rates</td>
</tr>
<tr>
<td>2014</td>
<td>JLN</td>
<td>India Aarogyasri Hospital</td>
<td>Case study</td>
<td>Top down, direct and indirect costing for operating and capital costs. For the cost of benefits packages a bottom-up approach was used. (4 hospitals; 42 procedures)</td>
<td>Costs of benefit packages</td>
<td>To set rates for 938 new benefit packages and revise estimates for pre-existing packages</td>
</tr>
<tr>
<td>2014</td>
<td>JLN</td>
<td>Indonesia casemix</td>
<td>Case study</td>
<td>Top-down costing (137 hospitals)</td>
<td>Not specified</td>
<td>To estimate the cost of health services and construct cost weights for case based payments.</td>
</tr>
<tr>
<td>Year</td>
<td>Author</td>
<td>Country/Region</td>
<td>Type of study</td>
<td>Method of cost data collection</td>
<td>Generated output (what form does the cost data take e.g. Unit costs, DRG cost weights, base rates)</td>
<td>What is/was the cost data used for or what is the intended use</td>
</tr>
<tr>
<td>------</td>
<td>--------</td>
<td>----------------</td>
<td>---------------</td>
<td>--------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------</td>
</tr>
<tr>
<td>2014</td>
<td>JLN</td>
<td>Indonesia</td>
<td>Case study</td>
<td>Top-down approach for both recurrent costs and capital costs. Bottom up approach to cost specific episodes of illness (200 hospitals)</td>
<td>Unit costs and episodes of illness</td>
<td>To estimate the production cost of services and drivers of cost variation among providers Capitation payments</td>
</tr>
<tr>
<td>2014</td>
<td>JLN</td>
<td>Central Asian Republic</td>
<td>Case study</td>
<td>Predominantly top down, but also bottom up to obtain allocation statistics (15 hospitals)</td>
<td>Cost per bed-day by department</td>
<td>To estimate the cost per bed-day by cost centres to inform DRG weight coefficients There was sufficient data available for top down costing which could be conducted in a relatively short period of time</td>
</tr>
<tr>
<td>2014</td>
<td>JLN</td>
<td>Malaysian DRG</td>
<td>Case study</td>
<td>Top-down approach to measure and value personnel, drugs/medical supplies, overheads, and capital resource use. Bottom up planned for ICU stays, laboratory tests and radiological interventions. (10 hospitals)</td>
<td>JLN costing exercise</td>
<td>To determine the cost of delivering health services in government hospitals to inform budgetary requirements Top down approach was used most of the time, but for items that were heterogeneous in their resource use or expensive a bottom up approach was more suitable</td>
</tr>
<tr>
<td>2014</td>
<td>JLN</td>
<td>Philippines</td>
<td>Case study</td>
<td>Analysis of claims. All tertiary hospitals.</td>
<td>Cost of health services and specific disease categories</td>
<td>PHFI used a mixed-method approach because data on resource use were not always available at the department level</td>
</tr>
<tr>
<td>2013</td>
<td>Chatterjee S et al</td>
<td>India</td>
<td>Primary (cost data)</td>
<td>Step down allocation; bottom up costing</td>
<td>Cost per OP visit, cost per bed day; cost per emergency visit, cost per OT case</td>
<td>Informs hospital administrators, to improve efficiency and demonstrate the feasibility of hospital cost analysis in India</td>
</tr>
<tr>
<td>2012</td>
<td>Riewpaiboon A.</td>
<td>Thailand</td>
<td>Primary (cost data)</td>
<td>1. Reimbursement price list; 2. Bottom up step down allocation; 3. Patient interviews</td>
<td>1. RVUs; 2. inpatient base rate; 3. patient non-medical costs</td>
<td>To develop a list of standard unit costs of medical services for Thailand for HTA</td>
</tr>
<tr>
<td>2012</td>
<td>Ministry of Health, Republic of Indonesia</td>
<td>Indonesia</td>
<td>Primary (cost data)</td>
<td>Step-down accounting methodology</td>
<td>For hospital services: cost per outpatient, cost per inpatient and cost per bed-day</td>
<td>To better understand the cost of delivering health services across the country and inform policy on geographic resource allocation, the development of hospital payment system and capitation formulae</td>
</tr>
<tr>
<td>Year</td>
<td>Author</td>
<td>Country/ Region</td>
<td>Type of study</td>
<td>Method of cost data collection</td>
<td>Generated output (what form does the cost data take e.g. Unit costs, DRG cost weights, base rates)</td>
<td>What is/was the cost data used for or what is the intended use</td>
</tr>
<tr>
<td>------</td>
<td>----------------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>2012</td>
<td>Martin A</td>
<td>Cambodia</td>
<td>Primary (cost data)</td>
<td>Top down costing/step-down cost accounting (10 hospitals)</td>
<td>Average cost per discharge, per inpatient data and per outpatient visit by hospital department</td>
<td>To link costs with funding sources and document use of funds as well as inform the revision of the National Charter on Health Financing including provider payment reforms.</td>
</tr>
<tr>
<td>2011</td>
<td>Mathauer I</td>
<td>Kenya</td>
<td>Literature review</td>
<td>Most recent, multi-site costing studies 1. Bottom up, ingredients costing from (11 faith-based provider hospitals - ); 2. Step down cost accounting model (22 private for profit hospitals)</td>
<td>Cost per case (surgical, non-surgical and outpatients); cost per bed-day (surgical and non-surgical)</td>
<td>Costing information to inform resetting health insurance remuneration rates</td>
</tr>
<tr>
<td>2011</td>
<td>Jassim AL et al</td>
<td>India</td>
<td>Primary (cost data)</td>
<td>Step down allocation; process costing</td>
<td>Cost per relative value unit in support cost centres (e.g. laboratory)</td>
<td>To improve costing accuracy and provide guidelines for improved costing at the hospital level</td>
</tr>
<tr>
<td>2009</td>
<td>Ghaffari S et al</td>
<td>Iran</td>
<td>Primary (cost data); cost modelling</td>
<td>Primary: Step down allocation; ABC costing; Cost modelling: DRG cost weights imported from Australia</td>
<td>Relative value units, DRG costs and cost weights using indirect costs, direct care services and costs of care</td>
<td>To guide costing efforts for case mix funding models and identify optimal method for costing given data constraints.</td>
</tr>
<tr>
<td>2009</td>
<td>Langebrunner JC et al</td>
<td>Kyrgyzstan</td>
<td>Case studies</td>
<td>Cost accounting: Step down cost allocation to departmental level, Adapted from US medicare cost reports (initially 1 public hospital)</td>
<td>Cost per bed day and cost per case</td>
<td>Informed case base payment rates in DRG system</td>
</tr>
</tbody>
</table>
For the studies reporting costs, cost per service unit at the hospital level was the most frequently sited output e.g., cost per bed day, cost per admission and cost per outpatient visit. Three studies generated unit costs for specific services: cost per adverse event [26]; laboratory services [32]; and pharmacy services [36]. And a further three studies generated costs of health benefit packages [16,25]\(^4\). Relative value units were the primary output of 7 studies, one of which also explicitly estimated an inpatient base rate [27].

Fourteen of the case studies were commissioned by the local ministry of health or agency acting on their behalf. However, in many cases, it was not clear who had commissioned the costing or if the study was linked to the national policy process [14,16,23,24,26,29,30,36]\(^4\). Two studies evaluated different methods for generating robust relative value units [30,34].

**Papers reporting on how cost data informs the tariff-setting process**

We identified 18 papers that provided explanation of the technical process of tariff-setting documenting experiences in 10 different countries (see Figure 3 and Error! Reference source not found.). Eight papers were published since the beginning of 2020, 8 papers in the period 2015-2019, 4 papers in the period 2010-2014, and 2 papers were published before 2010 (see Figure 4). The papers provided mixed levels of detail on the technical processes of price-setting and the strengths and weaknesses in each locality. The current tariff system, presence of an explanation of the price-setting process, the data used in price setting and resulting policy levers and implications are summarised in Figure 5.

Only one study described tariff setting in Africa [39]. The paper reviewed the available evidence on costs for informing Kenya’s National Health Insurance Fund prices and was published in 2011. Although the cost information were considered reliable by all stakeholders, in part due to their involvement in the costing exercises, the costs had not been used for setting prices at the time of the study.

---

\(^4\) Joint Learning Network case studies: India – Public Health Foundation of India
The other countries covered were all in Asia. In the Central Asia region, three papers focus on the reform of the tariff setting system in Kyrgyzstan [4,15,18]. The technical process of price setting is clearly documented. This process includes cost control measures derived from linking the reimbursement rates to the MOH budget. The Thai Universal Coverage Scheme (UCS) also provides an example in which cost control is built into the base rate through linkages to the budget. However, as figure 5 states, in Thailand, there are 3 government funded and implemented schemes. Although all Thai schemes use the same Thai-DRG grouper, the Civil Service Medical Benefit Scheme (CSMBS) and Social Health Insurance (SHI) schemes do not use cost control mechanisms, as the rates are not linked to an overall budget and are different rates for different hospitals [1,6,18,27].

The Kyrgyz reforms were found to be vulnerable to gaming as the system does not make full use of the data available potentially leading to misclassification of diagnoses. This potential for gaming is also highlighted in Iran. In contrast to the systematic introduction and use of cost accounting in Kyrgyzstan, Iran’s price setting process involves a technical assessment by an independent body but with limited transparency (see Figure 5) [33,34]. Dosh mangir et al note that without an objective and explicit mechanism in the updating of medical tariff and no structure to effectively manage conflicts of interest, the pricing system has in effect become “a tool for revenue manipulation” [33].

Challenges also arise when reimbursement rates are not based on cost evidence. In India’s national insurance programme for the poor and vulnerable, the government used existing information to set reimbursement rates while establishing a review system to allow for modification and improvement over time (see Figure 5) [15]. However, the method in which information from costing studies, experts and rates under previous schemes is compiled is not transparently reported on. Studies show that the rates vary considerably from actual costs (42% of HBPs had a price less than 50% of the true cost in 2018) [25]. This could affect the recruitment of providers, the coverage and quality of care, and bring the rates themselves into doubt [41]. Indonesia faces a similar problem in respect of laboratory services. Dianingati et al, report on a lack of transparency in the development of the reference prices set by the government and that the true costs of service delivery are 40-53% higher than the reference price. However, validation of the rates is difficult as data on the cost of healthcare
services is still limited to a few services, in focal geographical areas, restricted to the public sector with few published and readily accessible cost data analyses/ data sets [20,25].

Both the Thai UCS and Kyrgyz price-setting systems use cost accounting to inform their base rates and case weights. Langebrunner et al note how cost accounting has been used as an evaluation tool and allowed for tariff adjustments based on evidence so that payments match services in Kyrgyzstan. Similarly, in the Thai UCS scheme, a key feature of the tariff setting is the cost information on which pricing for the UCS is based. This is collected on a periodic basis in a cost survey and has evolved from initial work using an RVU method and “top level” hospital cost data [27] to a 900 hospital survey. While no study described how the system has reformed, the papers note that the gradual, step wise implementation allowed for institutional and technical capacity building.

There was less detail reported on the tariff setting process in China, Indonesia, Malaysia and Vietnam. The one study documenting tariff setting processes in China raises concerns that the schemes used retrospective payment system and fails to build in efficiency and cost control [18]. In Vietnam there was also concern that the fees and the payment schemes bore little relationship to the costs of delivering services although the relative value unit method used to calculate rates for the capitation scheme was relatively simple. Similarly, while the Malaysian system was designed for global budgeting, it also demonstrates that pricing evidence can be based on skeletal data sets such as those that focus on large expenditure items and patient data that are feasible to collect [1].

**DISCUSSION**

**Cost systems increase the policy evidence base**

Cost systems can create a transparent evidenced based process for price-setting and these systems need to generate good quality data, based on accepted methodologies. Studies from Iran and Thailand emphasise how important the cost system is in the setting of health benefit package/ DRG prices, to minimise gaming and prevent cost escalation [6,33]. Leaving base rates open to negotiation at the individual provider level with minimal evidence on costs and efficiency of service provision, leaves the system vulnerable to gaming.
Cost evidence can increase efficiency of service provision

Creating a tariff setting system that does not use costs based on empirical evidence can embed inefficiencies and possibly make it more difficult to implement costing in the future [33]. A centralised cost accounting system, such as was developed in Kyrgyzstan, was considered a major strength of the broader health system reforms – allowing for policy reform to anticipate expenditure needs and enabling the government to effect change more effectively.

Some data is better than no data but its important to plan early for sustainable institutionalized cost systems

On the other hand, it is also recognised that such exercises are expensive, and a persistent issue is that of overcoming the capacity constraints to generate this information. While obtaining good quality cost information can be an important aid to evidence-based decision-making, it is important to be aware of the trade off in accuracy and resources needed to generate the information. Where resources are highly constrained, any data can be better than no data, particularly if the data are reported transparently and how the data informs decisions is clearly communicated and accounted for. If cost accounting is not the norm and the budget is limited, costing for price setting may need to start with simpler methods, using, for example, expenditure data, relative value units and smaller samples of facilities. Alternative approaches, for example in India, Cambodia and Kenya, have started with the implementation of baseline multi-site costing studies. Although these are one off exercises, and therefore cannot identify drivers of efficiency, they provide an evidence base and good practice on which to build. The costing itself can be a way to bring stakeholders into the price setting process and build capacity for future costings.

The example of Kyrgyzstan shows how implementing a cost system is a slow, gradual and complex process. The established costing systems identified in the literature illustrate how a cost system has evolved from one-off exercises and developed into complex system with increasing numbers of participating providers (Thailand, Kyrgyzstan, China).
Costing needs and methods vary and need to be appropriate for the setting. Studies from Thailand and Vietnam compare different approaches to obtaining the base rate and cost weights for health technology assessment and pricing. They compare micro costing with relative value unit approaches and find both to be feasible with micro-costing being highly resource intensive. The costing methods tend to follow the same principles using top-down allocation methods supplemented with bottom-up costing if resources allow, for some specific inputs. In Malaysia, one study demonstrated the feasibility of using the electronic prescribing system to generate DRG weights, although it was recognised that these were not available in most facilities.

A transparent set of principles for translating cost evidence into base rates and weights is needed

As well as cost data collection, a systematic method for translating costs into prices or reimbursement rates helps avoid skewed incentives within the prices, evident in the unexplained differences between costs and reimbursement rates found in India and Indonesia [25,32]. Langenbrunner’s reporting of the Kyrgyzstan case study provides the most comprehensive description for the calculation of the base rate and case-based weightings and how to use these to set reimbursement rates [4]. Patharanarumol et al also describe the principles applied for estimating the base rates and weights in the Thai UCS scheme [6]. For both settings, explicitly accounting for the budget in the price estimation using an “economic adjustment” is a key mechanism of cost control. This level of transparency is not apparent elsewhere in the literature identified. For example, while the different strands of information used for price setting are documented in the reports on India, the method for combining this information is not reported [25,42]. And, in Iran, the lack of such a methodology was reported as a significant problem for the DRG system as a whole leading to price manipulation by different stakeholders [33].

Limitations

The scoping review has found a very limited level of evidence around how cost and price evidence is used in the price-setting process at the country level. In addition, many of the studies are old and may be outdated. While this can be in part due to the infancy of many of the price-setting systems and
reforms, the nature of the review may have limited the evidence generated. While early reforms might be reported for some countries, it was not possible to determine how the tariff-setting processes have evolved and are currently being implemented. For example, Vietnam’s pilot study was published in 2014 but there were no corresponding papers documenting next steps; nor did we identify more recent reports on Kenya and Cambodia where costing evidence from large multi-site studies were identified. Further, the terminology required to search for the role of cost evidence in price-setting in the literature is poorly defined. The terms cost and price are used in many different ways to mean different things which may have led to some omissions. In addition, during the screening process many articles were identified on the process of developing DRG type reforms, but few focussed on the price-setting process and how cost evidence is used in the price-setting process. To address this we extended the search and performed additional searches using the key words identified in the initial papers found that met the inclusion criteria. Our review of the grey literature was limited to a google search and snowballing from references that were identified in the initial search. It is likely evidence in this area lies in government and donor reports and we may have missed these. Restricting reports to the English language may have compounded this.

Despite these limitations and the few country case studies identified, consistent themes were evident around the need to use cost information using a systematic methodology, reporting this transparently and working with providers to develop the system. Our review confirms that cost evidence can increase efficiency of service provision by increasing the policy evidence base. To generate this evidence, countries need to build cost systems appropriate to the setting and data availability but allowing for and investing in increasing complexity as data systems improve. Even while national costing surveillance should be an aspiration, prices should be set using cost evidence which can take the form of one off costing studies, or even hospital charges. Especially in the absence of national surveillance, the method in which these data are then used to set base rates and price weights should be part of a transparent process that involves all stakeholders and takes account of heterogeneity in costs driven by demand side (e.g. condition or patient specific) and supply side (e.g. hospital location) factors.
CONCLUSION

LMICs are increasingly turning to insurance-based models of healthcare and private sector providers to increase coverage of the poor and vulnerable. To help achieve value for money within these universal health coverage goals, publicly financed insurance schemes need to account for budget constraints, encourage efficient health service delivery and use good quality evidence transparently in setting reimbursement rates. Documentation of the good practice and the challenges of generating cost evidence and creating costing systems for informing reimbursement decisions in resource poor settings are lacking. While there are accepted and widely used methods for generating cost information, countries need to build more sustainable cost systems and adopt more transparent systems and methodologies for translating costs into prices.

ACKNOWLEDGEMENTS

Grateful thanks to Yi-Ling Chi and Lydia Regan at Center for Global Development for valuable comments and advice to the search strategy.

COMPETING INTERESTS

HS contributed to this study whilst being employed for the Center for Global Development. HS is now an employee for GSK and holds shares in the GSK group of companies; all other authors declare no competing interests. LG declares fees for postgraduate teaching at London School of Hygiene and Tropical Medicine.

FUNDING

Financial support for this work came from the Bill & Melinda Gates Foundation Grant no: INV-003239.

AUTHORS’ CONTRIBUTIONS

- Concept and design: LG, HAS, SG, AM
- Acquisition of data: LG, SG
- Analysis and interpretation of data: LG, SG
- Drafting of the manuscript: HAS, LG, SG
- Critical revision of paper for important intellectual content: HAS, LG, SG
- Obtaining funding: LG, AM
- Supervision: LG, AM
REFERENCES


21 National Health Authority. Journey from HBP 1.0 to HBP 2.0. 2019.


23 Chatterjee S, Levin C, Laxminarayan R. Unit Cost of Medical Services at Different Hospitals in India. *PLoS ONE* 2013;8:e69728. doi:10.1371/journal.pone.0069728


Rasiah D. Why Activity Based Costing (ABC) is still tagging behind the traditional costing in Malaysia? *Journal of Applied Finance & Banking* 2011;83–106.


Figures

Figure 1: PRISMA diagram

![PRISMA diagram](image)

Figure 2: Number of papers by country breakdown and types of study

![Number of papers by country breakdown and types of study](image)
Figure 3. Number of papers explaining the tariff setting scheme by country

Figure 4. Number of papers by year of publication.
Figure 5 Summary of evidence on the tariff setting process for case-based hospital payment in national health insurance schemes

- **Kyrgyzstan**: Base rate informed by budget and adjusted based on case weights and service load
- **Vietnam**: Case-based payments in pilot phases. Payments based on historical data.
- **Cost data based on new building and patient data systems including cost accounting.**
- **Cost accounting used for evaluation.**
- **Capacity building, case rates based on evidence.**
- **Reimbursement rates do not reflect costs of service provision.**

- **China**: DRG systems with retrospective reimbursement and annual adjustments of the base rate based on negotiations.
- **Cost data based on discharge data and fee-for-service charge data.**

- **Iran**: Tariffs based revised annually by independent body.
- **Cost data based on historical hospital expenditures.**
- **Price system is not transparent, slow, and subject to gaming.**

- **Kazakhstan**: Regular review of approx. 3400 individual packages.
- **Indonesia**: Reference prices set by central government.
- **Not clear what the cost data is based on; laboratory service rates are based on existing charges.**
- **Reimbursement rates vary from costs of provision.**

- **Kenya**: Prospective payment scheme based on rates negotiated with each provider.
- **Cost data available but not used.**
- **No efficiency and cost control measures.**

- **India**: Proportional share of approx. 3400 individual packages.
- **A mix of cost data, expert consultation, and rates from pre-existing publicly funded insurance schemes.**
- **Prices adjustments for accredited and teaching providers to promote quality.**
- **Rates vary from actual costs of provision.**

- **South Korea**: Small proportion of approx. 3400 individual packages.
- **No cost control measures built into tariff system, but tariff setting process is not documented.**

- **Legend**:
  - Tariff setting process documented, no explicit cost control measures built in.
  - Cost control measures built into tariff system, but tariff setting process is not documented.
  - Neither.
  - Technical tariff setting process documented, explicit cost control measures built in.